NOMURA HOLDINGS INC-SPON ADR (NMR) Fundamental Analysis & Valuation

NYSE:NMR • US65535H2085

Current stock price

7.88 USD
-0.01 (-0.13%)
Last:

This NMR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. NMR Profitability Analysis

1.1 Basic Checks

  • In the past year NMR was profitable.
  • In the past year NMR had a positive cash flow from operations.
  • NMR had positive earnings in 4 of the past 5 years.
  • NMR had negative operating cash flow in 4 of the past 5 years.
NMR Yearly Net Income VS EBIT VS OCF VS FCFNMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B 1T -1T -1.5T

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.61%, NMR is doing worse than 67.78% of the companies in the same industry.
  • NMR's Return On Equity of 10.62% is fine compared to the rest of the industry. NMR outperforms 62.76% of its industry peers.
  • NMR has a worse Return On Invested Capital (0.68%) than 72.38% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for NMR is significantly below the industry average of 7.30%.
  • The last Return On Invested Capital (0.68%) for NMR is above the 3 year average (0.42%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROIC 0.68%
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
NMR Yearly ROA, ROE, ROICNMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

  • With a Profit Margin value of 8.05%, NMR is not doing good in the industry: 60.67% of the companies in the same industry are doing better.
  • In the last couple of years the Profit Margin of NMR has declined.
  • NMR's Operating Margin of 11.60% is on the low side compared to the rest of the industry. NMR is outperformed by 68.20% of its industry peers.
  • In the last couple of years the Operating Margin of NMR has declined.
  • NMR has a Gross Margin of 43.38%. This is comparable to the rest of the industry: NMR outperforms 46.03% of its industry peers.
  • NMR's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
NMR Yearly Profit, Operating, Gross MarginsNMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. NMR Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for NMR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NMR Yearly Shares OutstandingNMR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
NMR Yearly Total Debt VS Total AssetsNMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10T 20T 30T 40T 50T

2.2 Solvency

  • Based on the Altman-Z score of -0.22, we must say that NMR is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.22, NMR is doing worse than 81.59% of the companies in the same industry.
  • A Debt/Equity ratio of 10.65 is on the high side and indicates that NMR has dependencies on debt financing.
  • NMR has a Debt to Equity ratio of 10.65. This is amonst the worse of the industry: NMR underperforms 89.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Altman-Z -0.22
ROIC/WACCN/A
WACCN/A
NMR Yearly LT Debt VS Equity VS FCFNMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5T 10T

2.3 Liquidity

  • A Current Ratio of 0.27 indicates that NMR may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.27, NMR is doing worse than 84.10% of the companies in the same industry.
  • A Quick Ratio of 0.27 indicates that NMR may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.27, NMR is doing worse than 84.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.27
Quick Ratio 0.27
NMR Yearly Current Assets VS Current LiabilitesNMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T 20T 25T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. NMR Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.00% over the past year.
  • The Earnings Per Share has been growing by 19.69% on average over the past years. This is quite good.
EPS 1Y (TTM)8%
EPS 3Y58.58%
EPS 5Y19.69%
EPS Q2Q%4.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.53%

3.2 Future

  • The Earnings Per Share is expected to grow by 5.02% on average over the next years.
  • Based on estimates for the next years, NMR will show a small growth in Revenue. The Revenue will grow by 3.31% on average per year.
EPS Next Y4.05%
EPS Next 2Y5.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.76%
Revenue Next 2Y3.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NMR Yearly Revenue VS EstimatesNMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
NMR Yearly EPS VS EstimatesNMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 100

More info and screens

Find the best growth stocksShow best growing peers

4

4. NMR Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.73, the valuation of NMR can be described as very reasonable.
  • NMR's Price/Earnings ratio is a bit cheaper when compared to the industry. NMR is cheaper than 69.04% of the companies in the same industry.
  • NMR is valuated cheaply when we compare the Price/Earnings ratio to 26.91, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 9.33, which indicates a very decent valuation of NMR.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of NMR indicates a somewhat cheap valuation: NMR is cheaper than 74.06% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.99, NMR is valued rather cheaply.
Industry RankSector Rank
PE 9.73
Fwd PE 9.33
NMR Price Earnings VS Forward Price EarningsNMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • NMR's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NMR is cheaper than 66.11% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 20.48
NMR Per share dataNMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates NMR does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)2.4
PEG (5Y)0.49
EPS Next 2Y5.02%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. NMR Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 4.00%, NMR is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 6.53, NMR has a dividend in line with its industry peers.
  • NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 4%

5.2 History

  • On average, the dividend of NMR grows each year by 15.59%, which is quite nice.
  • NMR has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)15.59%
Div Incr Years0
Div Non Decr Years0
NMR Yearly Dividends per shareNMR Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

5.3 Sustainability

  • NMR pays out 45.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • NMR's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP45.53%
EPS Next 2Y5.02%
EPS Next 3YN/A
NMR Yearly Income VS Free CF VS DividendNMR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B -1T -1.5T
NMR Dividend Payout.NMR Dividend Payout, showing the Payout Ratio.NMR Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

NMR Fundamentals: All Metrics, Ratios and Statistics

NOMURA HOLDINGS INC-SPON ADR

NYSE:NMR (4/29/2026, 12:17:50 PM)

7.88

-0.01 (-0.13%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)04-24
Earnings (Next)07-27
Inst Owners43.35%
Inst Owner Change0.83%
Ins OwnersN/A
Ins Owner Change0%
Market Cap22.75B
Revenue(TTM)N/A
Net Income(TTM)370.05B
Analysts73.85
Price Target9.1 (15.48%)
Short Float %0.1%
Short Ratio1.17
Dividend
Industry RankSector Rank
Dividend Yield 4%
Yearly Dividend0.25
Dividend Growth(5Y)15.59%
DP45.53%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-4.65%
Max EPS beat(2)22.4%
EPS beat(4)2
Avg EPS beat(4)16.43%
Min EPS beat(4)-10.21%
Max EPS beat(4)58.19%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.31%
PT rev (3m)7.07%
EPS NQ rev (1m)-6.92%
EPS NQ rev (3m)-6.92%
EPS NY rev (1m)2.62%
EPS NY rev (3m)6.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.58%
Revenue NY rev (3m)3.84%
Valuation
Industry RankSector Rank
PE 9.73
Fwd PE 9.33
P/S 0.79
P/FCF N/A
P/OCF 5.74
P/B 1.04
P/tB 1.07
EV/EBITDA 20.48
EPS(TTM)0.81
EY10.28%
EPS(NY)0.84
Fwd EY10.72%
FCF(TTM)-0.57
FCFYN/A
OCF(TTM)1.37
OCFY17.43%
SpS9.96
BVpS7.56
TBVpS7.39
PEG (NY)2.4
PEG (5Y)0.49
Graham Number11.7359 (48.93%)
Profitability
Industry RankSector Rank
ROA 0.61%
ROE 10.62%
ROCE 1.68%
ROIC 0.68%
ROICexc 0.76%
ROICexgc 0.77%
OM 11.6%
PM (TTM) 8.05%
GM 43.38%
FCFM N/A
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.42%
ROIC(5y)0.41%
ROICexc(3y)0.46%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.09%
ROCE(5y)1.09%
ROICexgc growth 3Y16.87%
ROICexgc growth 5Y8.04%
ROICexc growth 3Y16.9%
ROICexc growth 5Y8.08%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score7
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 10.65
Debt/FCF N/A
Debt/EBITDA 62.4
Cap/Depr 1450.41%
Cap/Sales 19.46%
Interest Coverage 0.21
Cash Conversion 106.5%
Profit Quality N/A
Current Ratio 0.27
Quick Ratio 0.27
Altman-Z -0.22
F-Score7
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y58.58%
EPS 5Y19.69%
EPS Q2Q%4.11%
EPS Next Y4.05%
EPS Next 2Y5.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-46.53%
Revenue Next Year4.76%
Revenue Next 2Y3.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.03%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year27427%
EBIT Next 3Y537.53%
EBIT Next 5YN/A
FCF growth 1Y58.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y236.88%
OCF growth 3YN/A
OCF growth 5YN/A

NOMURA HOLDINGS INC-SPON ADR / NMR Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NOMURA HOLDINGS INC-SPON ADR?

ChartMill assigns a fundamental rating of 2 / 10 to NMR.


What is the valuation status of NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

ChartMill assigns a valuation rating of 4 / 10 to NOMURA HOLDINGS INC-SPON ADR (NMR). This can be considered as Fairly Valued.


How profitable is NOMURA HOLDINGS INC-SPON ADR (NMR) stock?

NOMURA HOLDINGS INC-SPON ADR (NMR) has a profitability rating of 2 / 10.


Can you provide the PE and PB ratios for NMR stock?

The Price/Earnings (PE) ratio for NOMURA HOLDINGS INC-SPON ADR (NMR) is 9.73 and the Price/Book (PB) ratio is 1.04.


Can you provide the expected EPS growth for NMR stock?

The Earnings per Share (EPS) of NOMURA HOLDINGS INC-SPON ADR (NMR) is expected to grow by 4.05% in the next year.